[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![oninvest_tech Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1805523934940741635.png) Oninvest [@oninvest_tech](/creator/twitter/oninvest_tech) on x XXX followers
Created: 2025-07-16 12:02:25 UTC

Freedom Eyes Viking Therapeutics Ahead of Key Obesity Drug Milestones

Freedom Broker sees upside in $VKTX, calling it a rare challenger to obesity drug giants Novo Nordisk and Eli Lilly. Two catalysts are due in H2: the launch of a Phase X trial for its injectable treatment VK2735, and interim data for the oral version.

Historically, Viking shares have rallied ahead of similar updates.

VK2735 has already shown stronger efficacy than Wegovy and Zepbound, which together control XX% of the GLP‑1 obesity market — a tight duopoly Viking may be poised to disrupt.

Freedom rates the stock Buy, with a $XX target (~20% upside). Wall Street is even more bullish, with an average target of $90.26, nearly 3x current levels.


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1945453966592016670/c:line.svg)

**Related Topics**
[stocks](/topic/stocks)
[eli](/topic/eli)
[$novcde](/topic/$novcde)
[novo](/topic/novo)
[$vik](/topic/$vik)
[$vktx](/topic/$vktx)
[eli lilly](/topic/eli-lilly)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/oninvest_tech/status/1945453966592016670)